<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927806</url>
  </required_header>
  <id_info>
    <org_study_id>PL-202108037M</org_study_id>
    <nct_id>NCT04927806</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Antimicrobial Breathing System on the Presence of Multidrug-resistant Organisms</brief_title>
  <official_title>The Effectiveness of Antimicrobial Breathing System on the Presence of Multidrug-resistant Organisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu Jen Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fu Jen Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigates the effectiveness of antimicrobial breathing system&#xD;
      on multidrug-resistant organisms (MDRO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Cross transmission via skin contact and environmental media is the main route for common&#xD;
      outbreak of health care-associated infection which more likely to be improved or prevented by&#xD;
      infection control program. Silver Knight uses silver ions to disrupt the normal enzymatic&#xD;
      activities of bacteria for reducing microbial growth within, and on, the surface of the&#xD;
      breathing systems. It functions as a safe, quick and effective catalyst to deactivate&#xD;
      pathogenic bacteria and prevent their proliferation. However, there was no study comparing&#xD;
      the standard ventilator circuit with Silver Knight. This study focuses on the effectiveness&#xD;
      of antimicrobial breathing system in MDRO which including carbapenem-resistant,&#xD;
      vancomycin-resistant and multi-drug resistant.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This is a prospective, randomized study in a single hospital in the intensive care unit.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      In this study, we conduct a cluster-randomized crossover, multicenter trial. There are two&#xD;
      groups:&#xD;
&#xD;
        1. Control group: standard ventilator circuit in odd number month.&#xD;
&#xD;
        2. Experimental group: Silver Knight in even number month This study is expected to recruit&#xD;
           200 subjects. During this period, the ventilator circuits are all routinely used, only&#xD;
           the tubing will not be discarded after use for specimen collection.And the MDRO on the&#xD;
           surfaces of ventilator circuits will be analyzed and evaluated.&#xD;
&#xD;
      Effect:&#xD;
&#xD;
      We expect the antimicrobial breathing system could be more effectively than the standard&#xD;
      ventilator circuit. The policy related to current ventilator circuit will be revised&#xD;
      according to the results of this study.&#xD;
&#xD;
      Key words:&#xD;
&#xD;
      Antimicrobial Breathing system, ventilator circuits, multidrug-resistant organisms (MDRO)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In this study, we conduct a cluster-randomized crossover, multicenter trial. This study is expected to recruit 200 subjects.There are two groups:&#xD;
Control group: standard ventilator circuit in odd number month.&#xD;
Experimental group: Silver Knight in even number month</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bacterial contamination</measure>
    <time_frame>one month</time_frame>
    <description>comparison of the two ventilator systems</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bacterial detection rate</measure>
    <time_frame>one month</time_frame>
    <description>comparison of the two ventilator systems</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bacterial Contamination</condition>
  <arm_group>
    <arm_group_label>SilverKnight group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silver Knight is an anti-microbial additive that uses silver ions to disrupt the normal enzymatic activities of bacteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group uses standard ventilator circuits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silver Knight</intervention_name>
    <description>Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:&#xD;
Staphyloccus epidermis&#xD;
Pseudomonas aeruginosa&#xD;
Klebsiella pneumoniae&#xD;
Acinetobacter calcoaceticus&#xD;
Escherichia coli</description>
    <arm_group_label>SilverKnight group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  mechanical ventilators in Medisive CareUnit (MICU)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Using ventilators for less than seven days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Lun Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Emergency and Critical Care Medicine, Fu Jen Catholic University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ke-Yun Chao, M.Sc</last_name>
    <phone>+886952909103</phone>
    <email>ck_qq@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fu Jen Catholic University Hospital, Fu Jen Catholic University</name>
      <address>
        <city>New Taipei City</city>
        <zip>24352</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke-Yun Chao, M.Sc</last_name>
      <phone>+886952909103</phone>
      <email>ck_qq@hotmail.con</email>
    </contact>
    <investigator>
      <last_name>Ke-Yun Chao, M.Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Zilahi G, Artigas A, Martin-Loeches I. What's new in multidrug-resistant pathogens in the ICU? Ann Intensive Care. 2016 Dec;6(1):96. doi: 10.1186/s13613-016-0199-4. Epub 2016 Oct 6. Review.</citation>
    <PMID>27714706</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>November 13, 2021</last_update_submitted>
  <last_update_submitted_qc>November 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fu Jen Catholic University</investigator_affiliation>
    <investigator_full_name>Ke-Yun, Chao</investigator_full_name>
    <investigator_title>Group leader of Respiratory Therapists</investigator_title>
  </responsible_party>
  <keyword>Bacterial contamination</keyword>
  <keyword>nosocomail infection</keyword>
  <keyword>bacterial detection rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

